IBUTAMOREN MESILATE ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
78	下垂体前葉機能低下症	1

78. 下垂体前葉機能低下症

---

臨床試験数 : 492 /  薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000874-92-PL (EUCTR)	22/03/2021	26/10/2020	A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficiency (GHD)	A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficiency (GHD) - LUM-201-01	Growth hormone deficiency MedDRA version: 20.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: LUM-201 INN or Proposed INN: Ibutamoren mesilate Other descriptive name: IBUTAMOREN MESILATE Product Name: LUM-201 INN or Proposed INN: Ibutamoren mesilate Other descriptive name: IBUTAMOREN MESILATE Product Name: LUM-201 INN or Proposed INN: Ibutamoren mesilate Other descriptive name: IBUTAMOREN MESILATE Trade Name: Norditropin INN or Proposed INN: recombinant human growth hormone Other descriptive name: recombinant human growth hormone Trade Name: Norditropin INN or Proposed INN: recombinant human growth hormone Other descriptive name: recombinant human growth hormone	Lumos Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 2	United States;Poland;Ukraine;Australia;Russian Federation;Israel;New Zealand